Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 21376 AL 21390

[A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy]

Pupyshev AB, Korolenko TA, Tikhonova MA.

Zh Vyssh Nerv Deiat Im I P Pavlova. 2016 Sep;66(5):515-540.

Evaluating Recall and Recognition Memory Using the Montreal Cognitive Assessment: Applicability for Alzheimer's and Huntington's Diseases

Van Liew C, Santoro MS, Goldstein J, Gluhm S, Gilbert PE, Corey-Bloom J.

Am J Alzheimers Dis Other Demen. 2016 Dec;31(8):658-663. doi: 10.1177/1533317516668573. Epub 2016 Sep 26.

Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders

Di Domenico F, Tramutola A, Butterfield DA.

Free Radic Biol Med. 2017 Oct;111:253-261. doi: 10.1016/j.freeradbiomed.2016.10.490. Epub 2016 Oct 24.

AMPK in Neurodegenerative Diseases

Domise M, Vingtdeux V.

Exp Suppl. 2016;107:153-177. doi: 10.1007/978-3-319-43589-3_7.

Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?

Jodeiri Farshbaf M, Ghaedi K.

Biometals. 2017 Feb;30(1):1-16. doi: 10.1007/s10534-016-9981-x. Epub 2016 Nov 16.

Are microRNAs true sensors of ageing and cellular senescence?

Williams J, Smith F, Kumar S, Vijayan M, Reddy PH.

Ageing Res Rev. 2017 May;35:350-363. doi: 10.1016/j.arr.2016.11.008. Epub 2016 Nov 27.

The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review

Manoharan S, Guillemin GJ, Abiramasundari RS, Essa MM, Akbar M, Akbar MD.

Oxid Med Cell Longev. 2016;2016:8590578. doi: 10.1155/2016/8590578. Epub 2016 Dec 27.

Eye movements in neurodegenerative diseases

MacAskill MR, Anderson TJ.

Curr Opin Neurol. 2016 Feb;29(1):61-8. doi: 10.1097/WCO.0000000000000274.

DNA damage in the oligodendrocyte lineage and its role in brain aging

Tse KH, Herrup K.

Mech Ageing Dev. 2017 Jan;161(Pt A):37-50. doi: 10.1016/j.mad.2016.05.006. Epub 2016 May 26.

Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)

Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, Fagan AM, Goate A, Marcus DS, Xiong C, Allegri RF, Chhatwal JP, Danek A, Farlow MR, Fox NC, Ghetti B, Graff-Radford NR, Laske C, Martins RN, Masters CL, Mayeux RP, Ringman JM, Rossor MN, Salloway SP, Schofield PR, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN).

Lancet Neurol. 2016 Dec;15(13):1317-1325. doi: 10.1016/S1474-4422(16)30229-0. Epub 2016 Oct 21.

The rationale for deep brain stimulation in Alzheimer's disease

Mirzadeh Z, Bari A, Lozano AM.

J Neural Transm (Vienna). 2016 Jul;123(7):775-783. doi: 10.1007/s00702-015-1462-9. Epub 2015 Oct 6.

Are blood-based protein biomarkers for Alzheimer's disease also involved in other brain disorders? A systematic review

Chiam JT, Dobson RJ, Kiddle SJ, Sattlecker M.

J Alzheimers Dis. 2015;43(1):303-14. doi: 10.3233/JAD-140816.

The use of pharmacological retromer chaperones in Alzheimer's disease and other endosomal-related disorders

Berman DE, Ringe D, Petsko GA, Small SA.

Neurotherapeutics. 2015 Jan;12(1):12-8. doi: 10.1007/s13311-014-0321-y.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias